Af­ter Tesaro buy, GSK wades deep­er in­to can­cer un­veil­ing big im­munother­a­py deal with Ger­many's Mer­ck

GSK is muscling its way in­to the can­cer big leagues, months af­ter agree­ing to shell out $5 bil­lion for can­cer drug­mak­er Tesaro. On Tues­day, the British drug­mak­er said it would co-de­vel­op a fu­sion pro­tein im­munother­a­py — de­signed to of­fer fresh ways to fight dif­fi­cult-to-treat can­cers be­yond the ex­ist­ing PD-1/PD-L1 class — with Ger­many’s Mer­ck KGaA in a deal val­ued up to about $4.2 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER